Atractylenolide III Enhances Energy Metabolism by Increasing the SIRT-1 and PGC1α Expression with AMPK Phosphorylation in C2C12 Mouse Skeletal Muscle Cells
- 1 January 2017
- journal article
- Published by Pharmaceutical Society of Japan in Biological & Pharmaceutical Bulletin
- Vol. 40 (3), 339-344
- https://doi.org/10.1248/bpb.b16-00853
Abstract
Japan's largest platform for academic e-journals: J-STAGE is a full text database for reviewed academic papers published by Japanese societiesKeywords
This publication has 26 references indexed in Scilit:
- Cellular bioenergetics as a target for obesity therapyNature Reviews Drug Discovery, 2010
- PGC-1α, SIRT1 and AMPK, an energy sensing network that controls energy expenditureCurrent Opinion in Lipidology, 2009
- The Obesity, Metabolic Syndrome, and Type 2 Diabetes Mellitus Pandemic: Part I. Increased Cardiovascular Disease Risk and the Importance of Atherogenic Dyslipidemia in Persons With the Metabolic Syndrome and Type 2 Diabetes MellitusJournal of the CardioMetabolic Syndrome, 2009
- Resveratrol Improves Mitochondrial Function and Protects against Metabolic Disease by Activating SIRT1 and PGC-1αCell, 2006
- PGC-1α: a key regulator of energy metabolismAdvances in Physiology Education, 2006
- Metformin increases the PGC-1α protein and oxidative enzyme activities possibly via AMPK phosphorylation in skeletal muscle in vivoJournal of Applied Physiology, 2006
- Gateway to the metabolic syndromeNature Medicine, 2005
- Insulin Resistance in Morbid ObesityDiabetes, 2002
- Intramyocellular lipid concentrations are correlated with insulin sensitivity in humans: a 1 H NMR spectroscopy studyDiabetologia, 1999
- Effects of insulin on peripheral and splanchnic glucose metabolism in noninsulin-dependent (type II) diabetes mellitus.JCI Insight, 1985